Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 280,499	$ 179,338
Accounts receivable	58,834	60,587
Inventories	65,674	14,643
Deferred tax assets, net	1,710	0
Income tax receivable, net	1,357	5,651
Prepaid expenses and other current assets	24,101	12,896
Total current assets	432,175	273,115
Property, plant and equipment, net	313,979	264,240
In-process research and development	77,800	41,800
Intangible assets, net	58,344	30,148
Goodwill, net book value	41,984	13,954
Deferred tax assets, net	12,764	0
Other assets	8,216	3,373
Total assets	945,262	626,630
Current liabilities:
Accounts payable	40,930	27,521
Accrued expenses and other current liabilities	6,274	1,252
Accrued compensation	31,654	24,615
Contingent purchase consideration, current portion	6,487	1,341
Provision for chargebacks	2,246	0
Deferred tax liability, net	0	88
Short-term deferred revenue	5,345	1,834
Total current liabilities	92,936	56,651
Contingent purchase consideration, net of current portion	41,170	15,278
Long-term indebtedness, net of current portion	251,000	62,000
Deferred revenue, net of current portion	5,713	0
Deferred tax liability, net of current portion	0	1,419
Other liabilities	1,242	2,117
Total liabilities	392,061	137,465
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 38,129,872 shares issued and 37,709,683, shares outstanding at December 31, 2014; 37,036,996 shares issued and 36,624,043, shares outstanding at December 31, 2013	38	37
Treasury stock, at cost, 420,189 and 412,953 common shares at December 31, 2014 and 2013, respectively	(6,320)	(6,119)
Additional paid-in capital	274,222	247,637
Accumulated other comprehensive loss	(3,008)	(3,465)
Retained earnings	288,269	251,528
Total Emergent BioSolutions Inc. stockholders' equity	553,201	489,618
Noncontrolling interest in subsidiaries	0	(453)
Total stockholders' equity	553,201	489,165
Total liabilities and stockholders' equity	$ 945,262	$ 626,630